Home > Publications database > Nigrostriatal Upregulation of 5-HT2A Receptors Correlates with Motor Dysfunction in Progressive Supranuclear Palsy > print

001     5151
005     20180208231836.0
024 7 _ |2 pmid
|a pmid:19353726
024 7 _ |2 DOI
|a 10.1002/mds.22533
024 7 _ |2 WOS
|a WOS:000267511000009
037 _ _ |a PreJuSER-5151
041 _ _ |a eng
082 _ _ |a 610
084 _ _ |2 WoS
|a Clinical Neurology
100 1 _ |0 P:(DE-HGF)0
|a Stamelou, M.
|b 0
245 _ _ |a Nigrostriatal Upregulation of 5-HT2A Receptors Correlates with Motor Dysfunction in Progressive Supranuclear Palsy
260 _ _ |a New York, NY
|b Wiley InterScience
|c 2009
300 _ _ |a 1170 - 1175
336 7 _ |a Journal Article
|0 PUB:(DE-HGF)16
|2 PUB:(DE-HGF)
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|0 0
|2 EndNote
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a article
|2 DRIVER
440 _ 0 |0 9683
|a Movement Disorders
|v 24
|x 0885-3185
|y 8
500 _ _ |a This project was part of the Brain Imaging Center West (BICW) supported by the German Federal Ministry for Education and Research (BMBF, grant 01 G19934 to K.Z.), the Deutsche Forschungsgemeinschaft (DFG, Klinische Forschergruppe 112 to A.B.; HO2402/6-1 to G.H.), the International Consortium for Brain Mapping (ICBM grant to K.Z.), the Willy Robert Pitzer Foundation (to G.H./W.H.O.) and the von behringlrontgenlstiftung (56-0039 to G.H.).
520 _ _ |a A dysfunction of multiple neurotransmitter systems is assumed as a neurochemical basis of the akinetic-rigid syndrome of progressive supranuclear palsy (PSP). In vitro studies have produced conflicting results on the serotoninergic system in PSP. We, therefore, studied the binding potential of the serotonin 2A (5-HT(2A)) receptor ligand [18F]altanserin in 8 patients with clinically probable PSP and 13 healthy controls using positron emission tomography. We found an up-regulation of 5-HT(2A) receptors in the substantia nigra and, to a lower degree, in the striatum, while neocortical 5- HT(2A) receptor densities showed no changes upon partial-volume correction. Nigral and striatal receptor changes were significantly correlated with patients' scores of motor dysfunction (UPDRS III, PSP-rating scale) pointing to a functional relevance of the described findings.
536 _ _ |0 G:(DE-Juel1)FUEK409
|2 G:(DE-HGF)
|a Funktion und Dysfunktion des Nervensystems
|c P33
|x 0
588 _ _ |a Dataset connected to Web of Science, Pubmed
650 _ 2 |2 MeSH
|a Aged
650 _ 2 |2 MeSH
|a Brain Mapping
650 _ 2 |2 MeSH
|a Corpus Striatum: metabolism
650 _ 2 |2 MeSH
|a Corpus Striatum: radionuclide imaging
650 _ 2 |2 MeSH
|a Female
650 _ 2 |2 MeSH
|a Fluorine Radioisotopes: metabolism
650 _ 2 |2 MeSH
|a Humans
650 _ 2 |2 MeSH
|a Ketanserin: analogs & derivatives
650 _ 2 |2 MeSH
|a Ketanserin: metabolism
650 _ 2 |2 MeSH
|a Magnetic Resonance Imaging: methods
650 _ 2 |2 MeSH
|a Male
650 _ 2 |2 MeSH
|a Middle Aged
650 _ 2 |2 MeSH
|a Movement Disorders: etiology
650 _ 2 |2 MeSH
|a Movement Disorders: pathology
650 _ 2 |2 MeSH
|a Movement Disorders: radionuclide imaging
650 _ 2 |2 MeSH
|a Positron-Emission Tomography: methods
650 _ 2 |2 MeSH
|a Receptor, Serotonin, 5-HT2A: metabolism
650 _ 2 |2 MeSH
|a Statistics as Topic
650 _ 2 |2 MeSH
|a Substantia Nigra: metabolism
650 _ 2 |2 MeSH
|a Substantia Nigra: radionuclide imaging
650 _ 2 |2 MeSH
|a Supranuclear Palsy, Progressive: complications
650 _ 2 |2 MeSH
|a Supranuclear Palsy, Progressive: radionuclide imaging
650 _ 2 |2 MeSH
|a Up-Regulation: physiology
650 _ 7 |0 0
|2 NLM Chemicals
|a Fluorine Radioisotopes
650 _ 7 |0 0
|2 NLM Chemicals
|a Receptor, Serotonin, 5-HT2A
650 _ 7 |0 74050-98-9
|2 NLM Chemicals
|a Ketanserin
650 _ 7 |0 76330-71-7
|2 NLM Chemicals
|a altanserin
650 _ 7 |2 WoSType
|a J
653 2 0 |2 Author
|a PSP
653 2 0 |2 Author
|a Steele-Richardson-Olszewski syndrome
653 2 0 |2 Author
|a serotonin
653 2 0 |2 Author
|a 5-HT
653 2 0 |2 Author
|a 5-HT2A receptor
653 2 0 |2 Author
|a PET
700 1 _ |0 P:(DE-Juel1)138474
|a Matusch, A.
|b 1
|u FZJ
700 1 _ |0 P:(DE-Juel1)131679
|a Elmenhorst, D.
|b 2
|u FZJ
700 1 _ |0 P:(DE-Juel1)VDB32531
|a Hurlemann, R.
|b 3
|u FZJ
700 1 _ |0 P:(DE-HGF)0
|a Eggert, K.M.
|b 4
700 1 _ |0 P:(DE-Juel1)131714
|a Zilles, K.
|b 5
|u FZJ
700 1 _ |0 P:(DE-HGF)0
|a Oertel, W.H.
|b 6
700 1 _ |0 P:(DE-HGF)0
|a Höglinger, G.U.
|b 7
700 1 _ |0 P:(DE-Juel1)131672
|a Bauer, A.
|b 8
|u FZJ
773 _ _ |0 PERI:(DE-600)2041249-6
|a 10.1002/mds.22533
|g Vol. 24, p. 1170 - 1175
|p 1170 - 1175
|q 24<1170 - 1175
|t Movement disorders
|v 24
|x 0885-3185
|y 2009
856 7 _ |u http://dx.doi.org/10.1002/mds.22533
909 C O |o oai:juser.fz-juelich.de:5151
|p VDB
913 1 _ |0 G:(DE-Juel1)FUEK409
|a DE-HGF
|b Gesundheit
|k P33
|l Funktion und Dysfunktion des Nervensystems
|v Funktion und Dysfunktion des Nervensystems
|x 0
914 1 _ |y 2009
915 _ _ |0 StatID:(DE-HGF)0010
|a JCR/ISI refereed
920 1 _ |0 I:(DE-Juel1)INM-2-20090406
|k INM-2
|l Molekulare Organisation des Gehirns
|g INM
|x 0
920 1 _ |0 I:(DE-82)080010_20140620
|k JARA-BRAIN
|l Jülich-Aachen Research Alliance - Translational Brain Medicine
|g JARA
|x 1
970 _ _ |a VDB:(DE-Juel1)112593
980 _ _ |a VDB
980 _ _ |a ConvertedRecord
980 _ _ |a journal
980 _ _ |a I:(DE-Juel1)INM-2-20090406
980 _ _ |a I:(DE-82)080010_20140620
980 _ _ |a UNRESTRICTED
981 _ _ |a I:(DE-Juel1)VDB1046

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21